Administration of medroxyprogesterone acetate after endomyometrial resection

In: The Journal of the American Association of Gynecologic Laparoscopists · 1997 · vol. 4(2) , pp. 195–200 · doi:10.1016/s1074-3804(97)80009-6 · PMID:9057903 · W2129123265
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed View at publisher
AI-generated summary by claude@2026-07, 2026-07-28

Endometrial resection for menorrhagia reduced menstrual flow in all 70 patients, with 50% achieving amenorrhea, and only two requiring hysterectomy postoperatively.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Study objectiveTo assess the efficacy of endometrial resection for treatment of menorrhagia in women to whom no preoperative agent was given to prepare the endometrium.DesignRetrospective analysis of patients' records for all endometrial resections in which medroxyprogesterone acetate was used postoperatively.SettingHospital day surgery unit.PatientsSeventy patients with menorrhagia.InterventionsThe women underwent transvaginal sonography, followed by hysteroscopy and endometrial biopsy. The endometrium was removed using the 27F resectoscope followed by coagulation with the rollerball. Medroxy-progesterone acetate was prescribed for 2 months after surgery.Measurements and main resultsAll women achieved a reduction in menstrual flow and 50% reported amenorrhea after endometrial resection. In only two was hysterectomy necessary due to recurrence of menorrhagia.ConclusionPreoperative endometrial preparation was unnecessary when endometrial resection was carried out for treatment of menorrhagia. However, the patients received medroxyprogesterone acetate postoperatively.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

Cited by (2)

References (14)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-11T05:37:28.352103+00:00
License: CC0 · commercial use OK